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Sir,
We have read with great interest the article by Kim et al (2008),
in which they report the analysis of 713 cancer tissues for somatic
mutations in the AKT1, AKT2 and AKT3 genes. They detected the
previously reported AKT1 pleckstrin homology domain mutation
(AKT1 p.E17K) in 4 out of 93 (4.3%) breast carcinomas, but not in
the colorectal, lung, gastric and hepatocellular carcinomas of their
series (Carpten et al, 2007). The authors concluded that the AKT1
p.E17K mutation should be further analysed in a wider range of
cancers.
We have studied 118 carcinomas of the biliary tract and liver
(11 intrahepatic and 34 extrahepatic cholangiocarcinomas, 23
gallbladder carcinomas and 50 hepatocellular carcinomas) for
AKT1 p.E17K mutations using polymerase chain reaction (PCR)
and direct DNA sequencing. DNA was extracted from formalin-
fixed, paraffin-embedded tumour tissues. The primers for PCR
amplification and sequencing of exon 4 had the following
sequence: forward 50-CTGGCCCTAAGAAACAGCTCC-30 and
reverse 50-CGCCACAGAGAAGTTGTTGA-30. Reaction conditions
for PCR amplification were 40 cycles of 951C for 30s, 601C for
1min and 721C for 1min. Polymerase chain reaction products
were purified (GFX PCR DNA and Gel Band Purification Kit,
Amersham Biosciences, Otelfingen, Switzerland) and analysed on
an automated DNA sequencer (model 3130) using Gene Scan and
SeqScape software (Applied Biosystems, Foster City, CA, USA).
Nucleotide sequences were compared with the genomic sequence
of AKT1 (ENSG00000142208).
We did not observe AKT1 p.E17K mutations in any of the 118
carcinomas of the biliary tract and liver in our series.
We have recently shown that the frequent activation of the PI3K/
AKT pathway in carcinomas of the biliary tract and liver is
associated with PIK3CA hot spot mutations in a small subset of
these tumours (Riener et al, 2008). The low frequency of these
mutations lead to the conclusion that further genetic changes have
to be responsible for the activation of the PI3K/AKT pathway in
these cancers. The recently identified AKT1 p.E17K mutation
appeared to be a good candidate for such a mechanism. Our results
in hepatocellular carcinomas confirm the findings of Kim et al in a
different ethnic background and suggest that cholangiocarcinoma
and gallbladder carcinoma can be added to the list of cancers that
lack AKT1 p.E17K mutations.
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